43 results about "Systemic circulation" patented technology

The invention discloses an artificial heart valve near-physiological pulsation fluid external evaluation device and method, and relates to the technical field of heart valve testing.The artificial heart valve near-physiological pulsation fluid external evaluation device comprises a supporting frame, a driving unit, a tested valve installation unit and an artery and peripheral loop unit, the driving unit provides power for liquid flowing, and the tested valve installation unit is used for fixing an artificial heart valve; and a liquid volume assembly and a resistance assembly of the artery and peripheral loop unit can simulate the compliance and resistance of aorta blood vessels and peripheral artery blood vessels, so that the pressure waveform simulation of the systemic circulation loop is more accurate. On the basis of the air cavity, the elastic corrugated pipes with different frequency responses are arranged, the compliance and rebound resilience of the aorta are simulated, a device for rapidly replacing the tested valve is designed, and the mechanical property of the simulated human body aorta is adjusted by adjusting the parameters such as the output frequency and the vibration amplitude of the driving unit; real pressure and flow waveforms under different physiological / pathological conditions are simulated, and a more accurate and convenient detection environment is realized.

The invention provides a monitoring method, system and device based on a shared EIT wearable sensor and a medium, and the method comprises the steps: measuring the dynamic change of electrical impedance in a thoracic cavity through a sensor device attached to a chest region of a tested person, so as to collect signals related to pulmonary ventilation and blood flow; the collected signals related to lung ventilation and blood flow are subjected to signal processing, the pulmonary alveolar ventilation volume and the lung blood flow within unit time are calculated according to the signals so as to obtain the real-time ventilation / blood flow perfusion ratio, and regional analysis is carried out so that synchronous monitoring of the ventilation / blood flow perfusion ratios of different lung areas can be carried out. By sharing the EIT sensor array, synchronous monitoring of systemic circulation, pulmonary ventilation and the V / Q ratio is achieved, the number of used sensors is reduced, and the burden and medical cost of a patient are reduced. By combining an intelligent algorithm and a data fusion technology, comprehensive physiological information is provided, and a new solution is provided for personalized medical treatment and remote monitoring.

The invention relates to a control method of auxiliary breathing equipment, a controller, equipment and a storage medium. The auxiliary breathing equipment comprises a first cavity, a second cavity, a pipeline assembly and a gas driving assembly. The method comprises the following steps: periodically acquiring detection information of intra-pulmonary pressure during the period of providing ventilation support by the auxiliary breathing equipment; in response to the fact that the detection information of the intra-pulmonary pressure exceeds a preset pressure range, pressure reduction operation or pressure increase operation is executed to adjust the intra-pulmonary pressure to be within the preset pressure range; the decompression operation comprises the steps that the pipeline assembly and the gas driving assembly are controlled, so that redundant gas in the lung is exhausted to the external environment through the second cavity in the process of maintaining partial gas circulation of the lung between the first cavity and the lung; the pressurization operation comprises the steps that the pipeline assembly and the gas driving assembly are controlled, so that gas of the breathing gas source is introduced into the lung through the first cavity in the process of maintaining partial gas circulation of the lung between the second cavity and the lung. The safety of ventilation support can be improved.

The present invention discloses a method for evaluating the stability of antibody-drug conjugates, which includes using orthogonal experimental grouping to investigate the use of antioxidants, the participation of oxygen, and the incubation pH value, simulating the time of ADC drugs in the systemic circulation, investigating the changes in the appearance after long-term plasma incubation under different incubation conditions, and searching for specific metabolites. By comparing the peak intensities of specific metabolites, the incubation effect is evaluated. Only the system conditions that can detect specific predicted metabolites are considered to be the environments that normally produce metabolism. The intensity level of specific metabolites can be used to evaluate the quality of the incubation system conditions; the present invention for evaluating the stability of ADC drugs can effectively solve the problem of how to better extend the blood system incubation time, filling the blank of the stability evaluation system for this new type of drug, antibody-drug conjugates.

The invention relates to the technical field of medical health, and discloses a cardiopulmonary ultrasound assessment method and system for premature infant BPD early warning. The method comprises the steps that premature infant heart rate variability, pulmonary artery systolic pressure and respirator parameter data are synchronously collected through an HL7 FHIR protocol interface, and a BPD early warning basic data set is obtained; performing weighted fusion on the ratio of SDNN to RMSSD, the square ratio of pulmonary artery to systemic circulation systolic pressure and oxygenation parameters in the data through an algorithm to obtain a CPDI value; the CPDI and the cardiopulmonary parameters are combined to evaluate the pulmonary vascular resistance load, and a PVRL index is obtained; the CPDI, the PVRL, the gestational age and the body weight adjustment factor are fused, and a BPD occurrence risk score is obtained; and dividing risk levels according to the scoring interval and generating an early warning result. According to the method, the problem that premature infant BPD early warning lacks cardiopulmonary system multi-parameter fusion analysis and individualized risk assessment in the prior art is solved, and continuous dynamic early warning and accurate risk layering based on CPDI and PVRL indexes are achieved.

Methods and apparatus disclosed herein relate to graphical representation of patient hemodynamic state. In various embodiments, one or more measured physiological parameters of a patient may be analyzed. Based on the analysis, a graphical user interface (GUI) may be rendered. The GUI may include a figure-eight schematic (222, 1222) that represents a circulatory system of the patient. The figure-eight schematic may include: a first loop (224, 1224) that represents pulmonary circulation of the patient; a second loop (226, 1226) that represents systemic circulation of the patient; and a central object (228, 1228) that connects the first and second loops represents a heart of the patient. In various embodiments, each of the first and second loops includes multiple arc fragments, with each arc fragment being shaped to convey one or more of the measured physiological parameters of the patient.

The application provides an interventional ventricular auxiliary oxygen generation device, a blood flow channel crosses an aortic valve into a left ventricle from an ascending aorta, a blood inlet of the blood flow channel is located in the left ventricle, a blood outlet is located in the ascending aorta, a first conveying pipe and a second conveying pipe convey hydrogen peroxide and catalase into the left ventricle to generate oxygen and water through reaction, and a pumping unit pumps oxygen-rich blood in the left ventricle to the ascending aorta. The oxygen generation function is added to the ventricular auxiliary device, the oxygen-rich blood in the ventricle is pumped to the ascending aorta through the ventricular auxiliary device, which directly improves the myocardial hypoxia condition and helps the heart recover, and on the other hand, the oxygen-rich blood is pumped into the ascending aorta and directly participates in the systemic circulation, thereby directly and quickly improving the oxygen supply condition of the systemic circulation.

The invention relates to the technical field of medical instruments, in particular to an intrathoracic cardiac compression cardio-pulmonary resuscitation structure which comprises a case, an air supply part and a negative pressure part are fixedly mounted in the case, a storage box is fixedly connected to the inner wall of the case, and two hooks are integrally connected to the inner wall of the storage box. The storage box is fixedly connected with a sterile storage bag through the hook, a negative pressure pipeline, an air supply pipeline and an extrusion bag are stored in the sterile storage bag, one end of the air supply pipeline is used for being connected with an air supply part, and the other end of the air supply pipeline is used for being connected with the extrusion bag; one end of the negative pressure pipeline is used for being connected with the negative pressure part, and the other end of the negative pressure pipeline is used for being connected with the extrusion bag. The first air bag, the second air bag and the third air bag are used for carrying out partitioned extrusion on the heart, so that different pressure can be provided for systemic circulation and pulmonary circulation, and the physiological condition of a human body is better met.

Methods are provided for delivering a treatment therapy to treat an organ diagnosed with a disease state. The methods include delivering a first therapeutic agent into systemic circulation at a first flow rate, and delivering a second therapeutic agent directly into a vessel feeding the organ at a higher second flow rate than the first flow rate in a manner that prevents the second treatment agent from circulating systemically.

The embodiment of the application discloses a kind of vein bionics microfluidic chip and its preparation and application method of simulating multi-organ interconnection.The chip includes a chip main body, and its microfluid channel system integrates at least three organ simulation units: a lung simulation chamber for culturing lung cells to simulate upstream organs that can produce systemic effects;An upstream colon cancer cell culture chamber for three-dimensional culture of colon cancer cells to simulate tumor primary lesions;And a downstream liver cell culture chamber for three-dimensional co-culture of liver cells and vascular endothelial cells to simulate the target organ of liver, and the three simulation chambers are communicated with each other by a vein bionics microfluid network, which simulates the complex blood circulation system of human body (including pulmonary circulation and systemic circulation), can realize the signal molecule transmission between organs, and simulate the invasion and metastasis process of colon cancer cells to the target organ of liver via the circulatory system after being affected by upstream lung signals.

The present application relates to the technical field of medicine, and particularly relates to an anti-pulmonary fibrosis prodrug compound and a preparation method and application thereof. The prodrug compound is a novel prodrug, and the structure comprises: a) an active drug unit selected from pirfenidone and nintedanib; b) a lung targeting unit selected from diphenyl chloroiodonium salt and a mimic thereof 521; and c) a linker unit which is a responsive linkage sensitive to a biomarker specifically overexpressed in a pulmonary fibrosis microenvironment. The prodrug is stable in the systemic circulation and has no activity or low activity, and can be actively targeted to a pulmonary fibrosis lesion; under the specific stimulation of the PFM, the linker is broken, and the original drug molecule is accurately released, so that the concentration of the drug in the lesion site is significantly increased, the toxic side effects caused by systemic exposure are reduced, and the anti-pulmonary fibrosis effect is enhanced.

Disclosed herein are systems and methods for perfusing an organ while isolating the organ's venous and arterial circulation from the systemic circulation. In at least one embodiment, the organ is perfused with a therapeutic agent, such as an oncology drug.

The invention relates to an application of India giant globular bacteria in preparation of a medicine for regulating a tumor microenvironment, and belongs to the technical field of biological medicines. The invention provides an application of India giant globular bacteria XA-511 in preparation of a medicine for regulating a tumor microenvironment. Researches show that the India giant globular bacteria XA-511 can be colonized in a tumor microenvironment, the tumor microenvironment can be transformed through a metabolic pathway of the India giant globular bacteria XA-511, immune cell activation enhancement and the like, and cold tumors are transformed into hot tumors, so that the treatment effect of the immunosuppressor on tumors is promoted. Furthermore, treatment of secondary tumors is more difficult than primary tumors, since tumors may be present at multiple sites, and the volume and number of tumors may vary over time. And by virtue of the characteristic of a tumor hypoxia environment, the India giant globular bacteria XA-511 can be selectively colonized at a tumor occurrence part after entering a systemic circulatory system, so that the tumor microenvironment is specifically changed, and the treatment effect of the immunosuppressor on tumors is enhanced.

The utility model relates to the technical field of heart perfusion, in particular to a perfusing machine through heart systemic circulation, which comprises a perfusion needle and a perfusion machine body, and the perfusion needle comprises a puncture needle, a catheter, a fixing clamp and a rubber pad; when the animal heart is punctured, the puncture needle is punctured into the left atrium of the animal heart, then the fixing clamps are clamped and fixed to the two sides of the heart, at the moment, the animal heart is protected through the rubber pads, fixation of the puncture needle is completed, finally, the catheter is connected with a perfusion machine body, and the perfusion machine body can be started for a heart perfusion experiment. According to the perfusion needle, the puncture needle inserted into the heart is doubly fixed through the mousing hook and the fixing clamp on the puncture needle, the phenomenon that the puncture needle falls off during perfusion is effectively avoided, the animal heart is protected from being damaged by the fixing clamp through the arrangement of the rubber pad, and the problem that an existing heart perfusion experiment adopts a fixed perfusion needle, so that the perfusion needle is inconvenient to use is solved. The heart tissue is easily damaged, so that the perfusate flows out.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a drug-loaded microsphere as well as a preparation method and application thereof. According to the invention, the bioadhesive material is used as a carrier and is mixed with the drug to form the drug-loaded microspheres with nasal mucosa adhesiveness, so that the residence time of the drug in the nasal cavity is prolonged, meanwhile, the stimulation of the drug to the nasal mucosa is reduced, the bioavailability and intracerebral distribution are improved, the administration dosage is reduced, the sustained release effect of the drug is realized, and adverse reactions of gastrointestinal tracts and the like are avoided. The drug-loaded microsphere provided by the invention has the following characteristics: because the nasal mucosa area is large, submucosa blood vessels are very rich, and the drug can be rapidly absorbed and enter systemic circulation from the blood vessels; the first-pass effect during oral administration of the medicine is avoided, and the bioavailability is relatively high; a unique direct channel exists between the nasal cavity and the brain in anatomy, and various macromolecular polypeptides and small molecular drugs can bypass a blood-brain barrier to enter cerebrospinal fluid or brain tissue after being absorbed by the nose.

The present disclosure provides compositions and methods for the preparation and therapeutic use of vectorized antibodies, such as adeno-associated virus (AAV) vectors having viral genomes encoding one or more therapeutic antibodies or antibody fragments or antibody-like polypeptides having reduced stability outside of a tissue of interest. In some embodiments, the disclosure provides therapeutic antibodies comprising a sequence motif for increasing susceptibility of the therapeutic antibodies to protease degradation in systemic circulation. In some embodiments, the disclosure provides therapeutic antibodies comprising a variant Fc domain having reduced binding affinity to FcRn. The disclosure also provides use of the AAVs for the prevention and / or treatment of diseases and / or disorders of the central nervous system (CNS).

The application belongs to the technical field of medicine, and particularly relates to application of acacetin or 6-hydroxyflavone in preparation of anti-angina pectoris drugs, and aims to solve the problems of adverse reactions such as blood pressure drop, reflex tachycardia and the like caused by non-selective vasodilation of existing anti-angina pectoris drugs, wherein the drug improves myocardial blood supply by selectively dilating coronary vessels of the heart, wherein acacetin dilates coronary vessels of the heart by inhibiting cardiac coronary vessel myosin light chain kinase and activating myosin light chain phosphatase, and 6-hydroxyflavone dilates coronary vessels of the heart by inhibiting protein kinase C and enhancing myosin light chain phosphatase activity; and the acacetin or 6-hydroxyflavone significantly reduces the symptoms of myocardial ischemia of rats caused by isopropyl adrenaline, improves characteristic ECG abnormal changes of angina pectoris, does not affect heart rate and systemic blood pressure, and is safer, thereby providing a potential drug selection for anti-angina pectoris treatment.

This invention provides a systemic-pulmonary dual-circulation simulation system for testing the hemodynamic performance of an artificial heart. It includes a cardiovascular silicone model, a ventricular pulsation device, a controller, a data acquisition device, a fluid reservoir, and an artificial heart. The cardiovascular silicone model, ventricular pulsation device, and fluid reservoir are connected in series to form a blood circulation loop. The cardiovascular silicone model includes systemic and pulmonary circulation loops; the ventricular pulsation device has an internal electric cylinder that drives a piston to reciprocate via a push rod, causing fluid flow in the blood circulation loop; the controller controls the movement of the ventricular pulsation device to simulate blood flow with physiological pulsatile flow characteristics; the data acquisition device collects pressure and flow rate data at different locations on the cardiovascular silicone model. This invention can not only completely simulate the blood flow patterns of the human cardiovascular system but also be used to test the impact of artificial heart implantation on the hemodynamic performance of the human cardiovascular system under different physiological conditions, contributing to the development and research of artificial hearts.

A positive displacement pump that triggers with the beating of a mammalian heart, through the monitoring of an ECG signal is disclosed. A programmable delay from the detection of the forthcoming contraction of the heart enables the pump to syncopate the ejection of the fluid with the events occurring in the cardiovascular system. This delayed ejection could be used to overlay the ejected fluid from the pump with a pressure wave in the artery of systemic circulation through a catheter connection between the pump and a physiological model (e.g., cow, dog, human). The outcome of this use could be to raise the pulse pressure in the system to take advantage of physiological pathways that respond to this transient change in blood pressure. The novelty of this system stems from the adaptable control architecture designed to augment the pulsatile characteristics of the cardiovascular system. This inventive concept could be expanded to encompass the augmentation (dampen or enhance) of pulsatile characteristics in any oscillating flow system.

Provided herein are methods for delivering an agent (e.g., a therapeutic agent) preferentially to the heart, e.g., percutaneously, of a patient under conditions of cardiac arrest and isolation of cardiac circulation from systemic circulation. Also disclosed are methods of treating a cardiac condition in a patient using the methods of delivery.

The invention provides an interventional ventricular auxiliary oxygen generation device, a blood flow channel strides over an aortic valve from an ascending aorta to enter a left ventricle, a blood inlet of the blood flow channel is located in the left ventricle, and a blood outlet of the blood flow channel is located in the ascending aorta; the first conveying pipe and the second conveying pipe convey hydrogen peroxide and catalase into the left ventricle respectively to react to generate oxygen and water, and the pumping unit acts to pump oxygen-enriched blood in the left ventricle to the ascending aorta. An oxygen generation function is added to the ventricular auxiliary device, oxygen-enriched blood in the ventricle is pumped into the aorta through the ventricular auxiliary device, on one hand, the myocardial anoxia condition is directly improved, heart recovery is facilitated, on the other hand, the oxygen-enriched blood is pumped into the ascending aorta and directly participates in systemic circulation, and therefore the systemic circulation oxygen supply condition is directly and rapidly improved.

The invention provides a control method and device for a double-ventricle auxiliary system. The method comprises the following steps: acquiring a first parameter and a second parameter in a first period; adjusting the rotating speed of the first ventricular assist device or the second ventricular assist device according to the first parameter and the second parameter; acquiring a third parameter in a second period; and adjusting the rotating speed of the first ventricular assist device or the second ventricular assist device according to the third parameter, so that the cardiac function state of the target user is kept normal. The rotating speed of the ventricular assist device is adjusted according to the obtained physiological parameters of the user in the first period, so that the left ventricle of the user is in the normal operation state, and then the rotating speed of the ventricular assist device is adjusted by obtaining the adjusted physiological parameters of the user in the second period; the left heart and the right heart of the user are in a normal operation state, so that systemic circulation and pulmonary circulation of the user are kept balanced, the pumping effect of the double-ventricle auxiliary system is improved, and the heart failure symptom of the user is improved.

The present invention relates to the technical field of biomedicine, and particularly relates to a vascular flow simulation device for a systemic / pulmonary double circulation system based on hydraulic drive. It includes a systemic circulation simulation area, a pulmonary circulation simulation area, and a cardiac pulsation simulation area; by controlling solenoid valve I, solenoid valve II, solenoid valve III, solenoid valve IV, solenoid valve V, and solenoid valve VI, the cardiac pulsation simulation area simulates the blood pressure conditions during the isovolumetric contraction period, rapid ejection period, slow ejection period, pre-diastolic period, and diastolic period of the heart, and changing the switching frequency of the solenoid valve can change the simulated heart rate; at the same time, the systemic circulation simulation area is used to simulate the systemic circulation of the human body, and the pulmonary circulation simulation area is used to simulate the pulmonary circulation of the human body. Therefore, the present invention studies the situation when the systemic circulation and the pulmonary circulation interact. In addition, the present invention uses one power source to achieve the drive control of the systemic circulation and the pulmonary circulation, avoiding the problem that it is difficult for two power sources to be synchronized.

The application is a catheter pump with oxygen supply function which can improve oxygen supply of body circulation, the proximal end of the motor is connected with the catheter, the distal end is coaxially connected with an impeller, the outer periphery cover of the impeller is provided with a blood outflow cage, the distal end of the blood outflow cage is fixed with the proximal end of a blood inflow cage through a sleeve, the distal end of the blood inflow cage is further connected with a pigtail tube, an oxygen supply unit is arranged on the blood outflow cage, the oxygen supply unit generates oxygen according to physiological signals collected by a sensing unit in the ascending aorta according to time and demand, and releases the oxygen into the blood in the ascending aorta. In the process of assisting the heart to pump blood, the catheter pump can simultaneously supplement oxygen into the blood by using the oxygen supply unit, and improve the hypoxia condition of the whole body tissue. The oxygen supply unit is integrated on the catheter pump, and the catheter pump is intervened through the blood vessel together with the oxygen supply unit, so that the operation is simple, the damage to the blood vessel is reduced, the risk of gas embolism is reduced, the oxygen is better distributed, the oxygen supply mode is more in line with the physiological state, and the recovery of the patient is facilitated.

The invention relates to the technical field of biological medicine, in particular to a pharmaceutical composition for preventing and treating pulmonary arterial hypertension and a preparation method and application thereof. The invention provides a pharmaceutical composition for preventing and treating pulmonary arterial hypertension. The pharmaceutical composition is prepared from the following components: saltinib, azilsartan, baicalein, sinomenine and tanshinol. Different components are combined to treat pulmonary arterial hypertension, a good treatment effect is achieved, the composition can effectively reduce the pulmonary arterial pressure of an animal model and can also remarkably reduce systemic circulation pressure, the treatment effect of the composition is obviously superior to that of drugs in the prior art, and the composition has wide application prospects.

This invention discloses a parameter identification method for a lumped parameter model of systemic circulation, belonging to the field of lumped parameter model technology. The method includes: constructing the state equation of the lumped parameter model of systemic circulation based on Kirchhoff's voltage and current laws to obtain the systemic circulation control equation; calculating the duration ratio of systolic to diastolic phases and stroke volume based on routine clinical measurement data, constructing classic aortic pressure and flow waveforms, and performing registration processing; calculating central venous pressure and flow based on routine clinical measurement data; and using the registered aortic inlet pressure and flow, central venous pressure and flow, and systemic circulation control equations to calculate the values ​​of each parameter in the parameter model. This invention, by periodically stretching the classic reference waveform, matches the waveform extreme values ​​with the patient's measured blood pressure and cardiac output, indirectly reconstructing the aortic inlet pressure and flow curve reflecting individual characteristics under non-invasive conditions, significantly improving the model's individualization and clinical compatibility.

Provided herein are devices and methods for transdermal delivery of drugs into the systemic circulation, including a drug-loaded microneedle patch and a force-calibrated tractive counterpart. The tractive counterpart provides a force that is calibrated to hold the microneedles in the skin but not to impair capillary perfusion. Embodiments are described that comprise two microneedle patches, e.g., wherein the microneedles of one such patch are staggered with reference to the other patch, and wherein the weight of the patches is controlled to allow the device to remain in place despite movement of the subject who wears it.

Disclosed in certain embodiments is a parenteral formulation comprising a therapeutically effective amount of an emergency rescue active pharmaceutical ingredient and a parenterally acceptable adjuvant in an amount that enhances the absorption of the emergency rescue active pharmaceutical ingredient (ER-API) into the systemic circulation. The enhancement of absorption can be evidenced by a faster onset of action, a faster T max and / or a higher C max and / or a higher AUC last and / or a higher AUC 0.25 and / or a higher AUC 0.5 and / or a higher AUC 0.75 and / or a higher AUC1and / or increased bioavailability compared to a formulation without the adjuvant.

A clinical care system that integrates and analyzes patient data and applies rules to recommend potential treatments. A potential application is detection and management of shock, using hemodynamic data collected from devices such as a right heart catheter. The system may calculate confidence levels for each rule and present high-ranked treatment options to clinicians along with their confidence levels. Confidence levels for treatments may change continuously as a patient's condition evolves. For shock, features extracted from measured data may include for example a cardiac index (cardiac output divided by patient body surface area), systemic vascular resistance, and mean arterial pressure; treatment recommendations derived from these (and other) features may include administration of various medications such as epinephrine and vasopressin, installation of a ventricular assist device, transfusion, and volume resuscitation. Machine learning may be used to match recommendations to current clinical practice, or to optimize patient outcomes.

The invention provides a portal body shunt catheter suite which comprises a body vein catheter and a portal vein catheter, the first end of the body vein catheter is used for being placed in the internal jugular vein or the subclavian vein or the femoral vein, and the second end of the body vein catheter is used for being connected with the second end of the portal vein catheter; the first end of the portal vein catheter is used for being placed in an intrahepatic portal vein. The portal shunt catheter suite comprises the body vein catheter and the portal vein catheter which are connected with each other and work cooperatively, the purpose of portal shunt is achieved, the body vein catheter can be easily placed into the internal jugular vein, the subclavian vein or the femoral vein, and the portal vein catheter can be accurately placed into the intrahepatic portal vein. Blood accumulated in the portal vein of a patient is shunted into systemic circulation, then the portal vein pressure of the patient is reduced, symptoms caused by portal hypertension are relieved for the patient, risks such as esophageal and gastric fundus varicose vein bleeding and ascites can be reduced, and digestive tract bleeding caused by portal hypertension can be effectively treated.